Steven Keith Burke sold $106k of AKBA
SVP, Chief Medical Officer at Akebia Therapeutics, Inc.. 50,506 shares at an average of $2.10, traded Feb 3, 2025, filed Feb 4, 2025.
Score components
- +15RoleOfficer
- +10Trade size$106k at market
- 0Share of holdings soldSold 5.8% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-000916, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2025 | AGrant or award Common Stock10b5-1 | +194,900 | $0.00 | $0 | 866,740 | Feb 4, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -23,270 | $2.10 | $49k | 843,470 | Feb 4, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -27,236 | $2.10 | $57k | 816,234 | Feb 4, 2025 |
| Jan 31, 2025 | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +292,300 | $0.00 | $0 | 292,300 | Feb 4, 2025 |
Related signals
Other insiders at Akebia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | AKBAbuy Akebia Therapeutics, Inc. | John P. Butler CEO and President | $87k 69,270 shares | +2% | |
| 37Weak | Akebia Therapeutics, Inc. | John P. Butler CEO and President | $474k 341,305 shares | -10% | |
| 20Weak | Akebia Therapeutics, Inc. | Steven Keith Burke SVP, Chief Medical Officer | $94k 67,658 shares | -7% | |
| 25Weak | Akebia Therapeutics, Inc. | Nicholas Grund Chief Commercial Officer | $118k 84,829 shares | -13% | |
| 24Weak | Akebia Therapeutics, Inc. | Erik Ostrowski SVP, CFO, CBO & Treasurer | $49k 34,951 shares | -5% | |
| 23Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $69k 49,524 shares | -14% | |
| 25Weak | Akebia Therapeutics, Inc. | Carolyn M. Rucci SVP, Chief Legal Officer | $97k 69,772 shares | -11% | |
| 13Weak | Akebia Therapeutics, Inc. | Erik Ostrowski SVP, CFO, CBO & Treasurer | $152k 41,314 shares | -8% | |
| 0Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $60k 15,000 shares | -5% | |
| 1Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $47k 13,334 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.